Patents by Inventor Chang Kyu Heo

Chang Kyu Heo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230002485
    Abstract: The present invention relates to novel antibodies or antigen-binding fragments thereof that specifically bind to TransMembrane 4 Superfamily Member 4 (TM4SF4). These antibodies or antigen-binding fragments thereof exhibit proliferation inhibitory activity of cancer cells so as to effectively prevent or treat cancer, and reduce the self-renewal ability of cancer stem cells to be usefully used even in the treatments of cancer with a poor prognosis in conventional anticancer treatments.
    Type: Application
    Filed: December 4, 2020
    Publication date: January 5, 2023
    Inventors: In Gyu KIM, Rae Kwon KIM, Jai Ha LEE, Chang Kyu HEO, Yeon Jee KAHM, Byung Chul SHIN, Eun Wie CHO, Chun Jeih RYU, Min Kyu KIM, Mun Ju CHOI
  • Patent number: 10809263
    Abstract: Provided are an autoantibody specifically binding to an exosomal protein EIF3A (Eukaryotic translation initiation factor 3 subunit A) or a fragment including an antigen-binding site (paratope) thereof, a hybridoma cell line producing the autoantibody, a polypeptide having an amino acid sequence of an antigenic determinant (epitope) specifically binding to the autoantibody, a composition for diagnosing liver cancer including an agent measuring an expression level of the autoantibody or the fragment including the antigen-binding site thereof, a kit for diagnosing liver cancer including the composition, and a method of providing information for diagnosis of liver cancer by using the composition. Further, provided is a method of screening for a therapeutic agent for liver cancer by using an expression level of the autoantibody.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: October 20, 2020
    Assignees: PROTEOMETECH INC., KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Eun Wie Cho, Chang Kyu Heo, Hai Min Hwang, Jeong Heon Ko, Kook Jin Lim, Hye Jung Lee
  • Publication number: 20190204324
    Abstract: Provided are an autoantibody specifically binding to an exosomal protein EIF3A (Eukaryotic translation initiation factor 3 subunit A) or a fragment including an antigen-binding site (paratope) thereof, a hybridoma cell line producing the autoantibody, a polypeptide having an amino acid sequence of an antigenic determinant (epitope) specifically binding to the autoantibody, a composition for diagnosing liver cancer including an agent measuring an expression level of the autoantibody or the fragment including the antigen-binding site thereof, a kit for diagnosing liver cancer including the composition, and a method of providing information for diagnosis of liver cancer by using the composition. Further, provided is a method of screening for a therapeutic agent for liver cancer by using an expression level of the autoantibody.
    Type: Application
    Filed: July 8, 2016
    Publication date: July 4, 2019
    Applicants: Korea Research Institute of Bioscience and Biotechnology, ProteomeTech Inc.
    Inventors: Eun Wie Cho, Chang Kyu Heo, Hai Min Hwang, Jeong Heon Ko, Kook Jin Lim, Hye Jung Lee
  • Patent number: 8658769
    Abstract: The present invention relates to an autoantibody specifically recognizing the epitope sequence of FASN (fatty acid synthase), more particularly, to the autoantibody or a fragment comprising an antigen-binding site thereof, a diagnostic composition for hepatocellular carcinoma comprising an agent capable of assessing the expression level of the autoantibody, a hybridoma cell line producing the autoantibody, a diagnostic kit for hepatocellular carcinoma comprising the composition, a method for detecting the autoantibody of hepatocellular carcinoma patient using the composition, and a method for screening a therapeutic agent for hepatocellular carcinoma by administering candidate materials for hepatocellular carcinoma treatment to confirm a reduction in the expression level of autoantibody.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: February 25, 2014
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Eun Wie Cho, Chang Kyu Heo, Mi Kyung Woo, Hai Min Hwang, Hyang Sook Yoo, Jeong Heun Ko
  • Publication number: 20120264147
    Abstract: The present invention relates to an autoantibody specifically recognizing the epitope sequence of FASN (fatty acid synthase), more particularly, to the autoantibody or a fragment comprising an antigen-binding site thereof, a diagnostic composition for hepatocellular carcinoma comprising an agent capable of assessing the expression level of the autoantibody, a hybridoma cell line producing the autoantibody, a diagnostic kit for hepatocellular carcinoma comprising the composition, a method for detecting the autoantibody of hepatocellular carcinoma patient using the composition, and a method for screening a therapeutic agent for hepatocellular carcinoma by administering candidate materials for hepatocellular carcinoma treatment to confirm a reduction in the expression level of autoantibody.
    Type: Application
    Filed: October 1, 2010
    Publication date: October 18, 2012
    Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Eun Wie Cho, Chang Kyu Heo, Mi Kyung Woo, Hai Min Hwang, Hyang Sook Yoo, Jeong Heun Ko